Browse by Journal Title

Article

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
Briest, F. and Koziolek, E.J. and Albrecht, J. and Schmidt, F. and Bernsen, M.R. and Haeck, J. and Kühl, A.A. and Sedding, D. and Hartung, T. and Exner, S. and Welzel, M. and Fischer, C. and Grötzinger, C. and Brenner, W. and Baum, R.P. and Grabowski, P.
Neoplasia 23 (1): 80-98. January 2021

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera, M. and Fichtner, I. and Wulf-Goldenberg, A. and Sers, C. and Merk, J. and Patone, G. and Alp, K.M. and Kanashova, T. and Mertins, P. and Hoffmann, J. and Stein, U. and Walther, W.
Neoplasia 23 (1): 21-35. January 2021

Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.
Stein, U. and Arlt, F. and Smith, J. and Sack, U. and Herrmann, P. and Walther, W. and Lemm, M. and Fichtner, I. and Shoemaker, R.H. and Schlag, P.M.
Neoplasia 13 (2): 131-144. February 2011

Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer [Erratum in: Neoplasia. vol 6, pg 686, 2004].
Knoesel, T. and Schluens, K. and Stein, U. and Schwabe, H. and Schlag, P.M. and Dietel, M. and Petersen, I.
Neoplasia 6 (1): 23-28. 1 January 2004

Magnetic labeling of activated microglia in experimental gliomas.
Fleige, G. and Nolte, C. and Synowitz, M. and Seeberger, F. and Kettenmann, H. and Zimmer, C.
Neoplasia 3 (6): 489-499. 1 January 2001